We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. ×
Market Research Report

Global Kaposi Sarcoma Market Report by Product, by Distribution Channel, by Gender With COVID-19 impact | Forecast Period 2017-2030

Published Date :

2020-09-01

Report Pages :

740

Format :

PDF

Region Covered :

Global

Global Kaposi Sarcoma Market Overview

Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels, abnormal cells of KS form purple, red, or brown blotches or tumors on the skin called as lesions. Types of Kaposi Sarcoma are:

  • Epidemic (AIDS-related) Kaposi sarcoma

  • Classic (Mediterranean) Kaposi sarcoma

  • Endemic (African) Kaposi sarcoma

  • Iatrogenic (transplant-related) Kaposi sarcoma

  • Kaposi sarcoma in HIV negative men who have sex with men

Epidemic or AIDS-related KS is the most common type, develops in people who are infected with HIV, the virus that causes AIDS. In US, treatment of HIV infection with highly active antiretroviral therapy (HAART) has upshot the cases of epidemic KS and still some patients develop symptoms of KS in the initial months of HAART treatment.

In US, with the AIDS epidemic, the rate of KS increased more than 20 times — peaking at about 47 cases per million people (per year) in the early 1990s. Early in the AIDS epidemic, patients infected with HIV in the US were estimated to have a 50% probability of having KS. Transplant patients are another slot that gets KS, about 1 in 200 transplant patients in the United States gets KS.

“Imiquimod” (Aldara) is a topical drug that attunes the immune system and can be applied to the skin to treat certain kinds of warts and helping shrink KS skin lesions, as well. Similarly, Maraviroc (Selzentry) is also an antiretroviral drug currently being studied for its effect on Kaposi Sarcoma.

Global Kaposi Sarcoma Market Segmentation

By Diagnosis

  • Biopsy

  • Imaging

  • X-ray

  • Computed tomography (CT or CAT) scan

  • Endoscopy

  • Bronchoscopy

By Treatment

  • Antiretroviral Therapy (HAART)

  • Chemotherapy

  • Immunotherapy

By End User

  • Hospital

  • Diagnostic centers

  • Clinics

By Geography

  • North America (US, Canada) {Market Share (%), Market Size (USD Billion), Diagnosis (Number)}

  • Europe (UK, France, Italy, Germany, Spain, Hungary, Sweden, Russia, Poland and Rest of Europe) {Market Share (%), Market Size (USD Billion), Diagnosis (Number)}

  • Middle East and Africa (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) {Market Share (%), Market Size (USD Billion), Diagnosis (Number)}

  • Latin America (Brazil, Mexico and Rest of Latin America) {Market Share (%), Market Size (USD Billion), Diagnosis (Number)}

  • Asia Pacific (China, Japan, India, Singapore, South Korea, Australia, New Zealand and Rest of Asia-Pacific) {Market Share (%), Market Size (USD Billion), Diagnosis (Number)}

  • Rest of the World {Market Share (%), Market Size (USD Billion), Diagnosis (Number)}

Drivers and Challenges to Market Growth

Looming patent expiries of several blockbuster drugs, high rate of diagnosis of the condition, the easy availability of drugs, with the AIDS being epidemic, significant growth in the organ transplant procedures and introduction of innovative and generic drug as well as therapies are bolstering underlying demand for Kaposi Sarcoma market.

High cost across developing and less developed economies, shortage in supply of drugs due to wide demand-supply gap and less awareness among people limiting Kaposi sarcoma market growth prospects.  

Market Size and Forecast (2017-2030)

Kaposi sarcoma market is making strides. According to Goldstein Research, global Kaposi sarcoma market has increased at a CAGR of 2.25% over the forecast period to 2017-2030.

Based on treatments, antiretroviral therapy dominated the global Kaposi sarcoma market owing to the high incidence rate of AIDS-related Kaposi sarcoma and tends to grow at an encouraging pace in the forecast period as well. Biopsy is the first step to diagnose the Kaposi sarcoma while CT scan is usually done to determine if the cancer has spread to the lymph nodes, liver and lungs.

From region wise standpoint, North America is the leading contributor of revenue to the global Kaposi sarcoma market owing to high rate of diagnosis of the condition and the easy availability of drugs. Middle East and Africa region is the promising market of Kaposi sarcoma attributable to increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa.

Cover in the Global Kaposi Sarcoma market report

Market Synopsis

Market Segmentation

Global Kaposi Sarcoma Market is segmented as follows:

  • By diagnosis (Market Size, Demand Analysis and Growth Analysis)

  • By treatment (Market Size, Demand Analysis and Growth Analysis)

  • By end-user (Market Size, Demand Analysis and Growth Analysis)

Global Kaposi Sarcoma market report covered insights of below mentioned regions:

  • North America (U.S., Canada) {Market Size, Growth Analysis and Opportunity Analysis}

  • Latin America (Argentina, Mexico, Brazil and Rest of Latin America) {Market Size, Growth Analysis and Opportunity Analysis}

  • Europe (Germany, Italy, Spain, France, The U.K., Netherlands, Sweden, Hungary, Russia, Poland, Rest of Europe) {Market Size, Growth Analysis and Opportunity Analysis}

  • Asia-Pacific (China, India, Singapore, Japan, Australia, New Zealand, South Korea and Rest of Asia Pacific) {Market Size, Growth Analysis and Opportunity Analysis}

  • Middle East and North Africa (MENA) {Market Size, Growth Analysis and Opportunity Analysis}

  • Rest of World {Market Size, Growth Analysis and Opportunity Analysis}

Market Dynamics: Growth Drivers, Restraints and Opportunities

  • Risk Factors

  • Regional Variations

  • Current Trends and Developments

COVID-19 imapct on "Global Kaposi Sarcoma Market "    

Impact of COVID-19 Outbreak on “Global Kaposi Sarcoma Market e”, Manufacturers, Contract Manufacturers Suppliers and Recovery Strategy. A complete detailed chapter of 50-70 pages which includes the data and information focused on impacts of the pandemic on the Global Kaposi Sarcoma Market . It also showcases the expected recovery schedule and losses in the industry and other various major factors.

Key Market Players

  • Quest Diagnostics

o Synopsis

o Business Strategy

o Product Portfolio

o SWOT Analysis

  • Johnson & Johnson

  • Merck & Co. Inc.

  • Bristol Myers Squibb

  • Hoffman-La Roche Inc.

  • Pfizer Inc.

  • GlaxoSmithKline plc

  • Eli Lilly and Co

  • Navidea Biopharmaceuticals, Inc.

  • MBio Diagnostics

  • Cleveland Clinic

  • Massachusetts General Hospital

  • Mayo Foundation for Medical Education and Research (MFMER)

  • The Johns Hopkins Hospital

  • UCLA Health

  • Royal Adelaide Hospital

  • Cancer Institute Nsw

  • Vancouver Coastal Health

Porter’s Five Force Model

Market Landscape: Competition and Beyond

Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem

Expert Analysis

Concluding Remarks




{ }

Global Kaposi Sarcoma Market Report by Product, by Distribution Channel, by Gender With COVID-19 impact | Forecast Period 2017-2030

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747

Table of Contents

Please Select Linenece Type